High Triglyceridemia - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 97 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

High Triglyceridemia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'High Triglyceridemia - Pipeline Review, H2 2014', provides an overview of the High Triglyceridemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of High Triglyceridemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for High Triglyceridemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the High Triglyceridemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the High Triglyceridemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for High Triglyceridemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding High Triglyceridemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
High Triglyceridemia Overview 9
Therapeutics Development 10
Pipeline Products for High Triglyceridemia - Overview 10
Pipeline Products for High Triglyceridemia - Comparative Analysis 11
High Triglyceridemia - Therapeutics under Development by Companies 12
High Triglyceridemia - Therapeutics under Investigation by Universities/Institutes 14
High Triglyceridemia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
High Triglyceridemia - Products under Development by Companies 18
High Triglyceridemia - Products under Investigation by Universities/Institutes 19
High Triglyceridemia - Companies Involved in Therapeutics Development 20
Acasti Pharma Inc. 20
Actavis plc 21
Alnylam Pharmaceuticals, Inc. 22
Arisaph Pharmaceuticals, Inc. 23
Astellas Pharma Inc. 24
AstraZeneca PLC 25
Cardax Pharmaceuticals, Inc. 26
Catabasis Pharmaceuticals, Inc. 27
Essentialis, Inc. 28
Isis Pharmaceuticals, Inc. 29
Novartis AG 30
Pharmena SA 31
Poxel SA 32
Tekmira Pharmaceuticals Corp. 33
Thetis Pharmaceuticals LLC 34
Trygg Pharma AS 35
High Triglyceridemia - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
AKR-963 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ALN-AC3 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ALN-ANG - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ARI-3037MO - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AS-1708727 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
bezafibrate ER - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CAT-2003 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CDX-085 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
diazoxide choline CR - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ISIS-APOCIIIRx - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
KBCV-001 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MAT-9001 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
NKPL-66 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
pradigastat sodium - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
RNAi Oligonucleotide for Hypertriglyceridemia - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecule to Agonize Farnesoid X Receptor for Metabolic Disorders, Cardiovascular and Gastrointestinal Disorders - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
TP-101 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
TP-110 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
TP-252 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
TP-8252 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
TRIA-662 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
High Triglyceridemia - Recent Pipeline Updates 75
High Triglyceridemia - Dormant Projects 88
High Triglyceridemia - Discontinued Products 89
High Triglyceridemia - Product Development Milestones 90
Featured News & Press Releases 90
Oct 20, 2014: Matinas BioPharma Submits Investigational New Drug Application for Lead Product Candidate MAT9001 for the Treatment of Severe Hypertriglyceridemia 90
Sep 30, 2014: Matinas BioPharma to Present at the 13th Annual BIO Investor Forum on Wednesday, October 8, 2014 90
Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results 91
Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C 91
Sep 04, 2014: Matinas BioPharma to Present at Three Investor Conferences in September 93
Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014 94
Jul 24, 2014: Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston 94
Jan 10, 2014: Matinas BioPharma Announces Presentation at Biotech Showcase 2014 in San Francisco on Tuesday, January 14, 2013 95
Dec 05, 2013: Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Severe Hypertriglyceridemia 95
Nov 11, 2013: Acasti Completes PK IND Submission 95
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 97
Disclaimer 97

List of Tables
Number of Products under Development for High Triglyceridemia, H2 2014 10
Number of Products under Development for High Triglyceridemia - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
High Triglyceridemia - Pipeline by Acasti Pharma Inc., H2 2014 20
High Triglyceridemia - Pipeline by Actavis plc, H2 2014 21
High Triglyceridemia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 22
High Triglyceridemia - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2014 23
High Triglyceridemia - Pipeline by Astellas Pharma Inc., H2 2014 24
High Triglyceridemia - Pipeline by AstraZeneca PLC, H2 2014 25
High Triglyceridemia - Pipeline by Cardax Pharmaceuticals, Inc., H2 2014 26
High Triglyceridemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2014 27
High Triglyceridemia - Pipeline by Essentialis, Inc., H2 2014 28
High Triglyceridemia - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 29
High Triglyceridemia - Pipeline by Novartis AG, H2 2014 30
High Triglyceridemia - Pipeline by Pharmena SA, H2 2014 31
High Triglyceridemia - Pipeline by Poxel SA, H2 2014 32
High Triglyceridemia - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014 33
High Triglyceridemia - Pipeline by Thetis Pharmaceuticals LLC, H2 2014 34
High Triglyceridemia - Pipeline by Trygg Pharma AS, H2 2014 35
Assessment by Monotherapy Products, H2 2014 36
Number of Products by Stage and Target, H2 2014 38
Number of Products by Stage and Mechanism of Action, H2 2014 40
Number of Products by Stage and Route of Administration, H2 2014 42
Number of Products by Stage and Molecule Type, H2 2014 44
High Triglyceridemia Therapeutics - Recent Pipeline Updates, H2 2014 75
High Triglyceridemia - Dormant Projects, H2 2014 88
High Triglyceridemia - Discontinued Products, H2 2014 89